Monoclonal antibody-based immunotherapy is now considered to be a main component of
cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies …

It has been more than three decades since the first monoclonal antibody was approved by
the United States Food and Drug Administration (US FDA) in 1986, and during this time …

Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

Antibodies are the most rapidly growing drug class and have a major impact on human
health, particularly in oncology, autoimmunity and chronic inflammatory diseases. Many of …

Monoclonal antibodies are being developed as therapeutics to complement drugs and
vaccines or to fill the gap where no drugs or vaccines exist. These therapeutic antibodies …

The use of monoclonal antibodies as therapeutics requires optimizing several of their key
attributes. These include binding affinity and specificity, folding stability, solubility …

The remarkable progress in engineering and clinical development of therapeutic antibodies
in the last 40 years, after the seminal work by Köhler and Milstein, has led to the approval by …

Since the first monoclonal antibody drug, muromonab-CD3, was approved for marketing in
1986, 165 antibody drugs have been approved or are under regulatory review worldwide …

N-glycosylation of therapeutic antibodies starts as a co-translational step followed by a set of
post-translational modifications and is considered as one of the critical quality attributes …

Cell-surface Fcγ receptors mediate innate and adaptive immune responses. Human Fcγ
receptor I (hFcγRI) binds IgGs with high affinity and is the only Fcγ receptor that can …